1. Home
  2. SNGX vs LGVN Comparison

SNGX vs LGVN Comparison

Compare SNGX & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$1.23

Market Cap

12.0M

Sector

Health Care

ML Signal

HOLD

Logo Longeveron Inc.

LGVN

Longeveron Inc.

HOLD

Current Price

$0.99

Market Cap

11.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNGX
LGVN
Founded
1987
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.0M
11.9M
IPO Year
2006
2021

Fundamental Metrics

Financial Performance
Metric
SNGX
LGVN
Price
$1.23
$0.99
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$6.00
$6.50
AVG Volume (30 Days)
108.6K
7.1M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$119,371.00
$709,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.02
$0.48
52 Week High
$6.23
$1.92

Technical Indicators

Market Signals
Indicator
SNGX
LGVN
Relative Strength Index (RSI) 52.45 72.52
Support Level $1.19 $0.55
Resistance Level $1.22 $0.99
Average True Range (ATR) 0.06 0.11
MACD 0.02 0.04
Stochastic Oscillator 60.27 80.42

Price Performance

Historical Comparison
SNGX
LGVN

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About LGVN Longeveron Inc.

Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

Share on Social Networks: